Compare surgery timing with chemotherapy in advanced ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 3 trial tests whether patients with advanced ovarian, fallopian tube, or primary peritoneal cancer do better with surgery first versus chemotherapy first. It also groups people based on how extensive the cancer is to choose the best approach.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older (for one part, you must be under 70).
- You have confirmed stage IIIC or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
- Your cancer’s complexity score (cPCI) must fit one of the study’s ranges for Part 1 or Part 2.
- You should be able to do most daily activities (ECOG performance status 0–2 in Part 1, 0–1 in Part 2).
- You must be healthy enough for chemotherapy and surgery (bone marrow, kidney, and liver labs must be adequate).
- You must not have certain cancer types (like low-grade, mucinous, or clear cell) and must be able to follow the study plan and consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether the timing of surgery after chemotherapy can be personalized for advanced ovarian cancer. It uses a blood test (CA125) to help decide the best time for surgery, aiming to improve outcomes.
This trial checks whether having surgery to remove as much tumor as possible, followed by ongoing targeted treatment, helps people with advanced ovarian (and related) cancers live longer and/or control cancer better. It specifically uses tumor-testing results to match patients and then continues treatment after surgery.
This trial checks if adjusting the timing of surgery (interval debulking surgery) after chemotherapy can improve outcomes for people with advanced ovarian cancer. It's for those who cannot have surgery right away and will receive chemotherapy first.
This trial studies whether an additional treatment after surgery can help people with early-stage epithelial ovarian cancer live longer and stay well for more time. It is meant for patients who had a detailed staging operation and are able to start treatment within 8 weeks.
This trial tests a new combination of two immunotherapy drugs plus standard chemotherapy before surgery for advanced ovarian cancer. The goal is to see if this treatment shrinks the cancer more and makes surgery more effective.
This trial tests whether doing additional surgery to remove visible tumor (“secondary cytoreduction”) before chemotherapy helps compared with chemotherapy alone. It’s for ovarian (or related) cancer that came back after prior PARP inhibitor maintenance and platinum chemotherapy.
Hear when a new Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.